Long-term combination therapy of ezetimibe and acarbose for non-alcoholic fatty liver disease
Open Access
- 8 June 2009
- journal article
- Published by Elsevier BV in Journal of Hepatology
- Vol. 51 (3), 548-556
- https://doi.org/10.1016/j.jhep.2009.05.017
Abstract
No abstract availableThis publication has 21 references indexed in Scilit:
- Combination Therapy for Treatment or Prevention of AtherosclerosisHypertension, 2008
- Dietary cholesterol, rather than liver steatosis, leads to hepatic inflammation in hyperlipidemic mouse models of nonalcoholic steatohepatitisHepatology, 2008
- Effect of a Multifactorial Intervention on Mortality in Type 2 DiabetesThe New England Journal of Medicine, 2008
- Ezetimibe improves liver steatosis and insulin resistance in obese rat model of metabolic syndromeFEBS Letters, 2007
- Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised studyCurrent Medical Research and Opinion, 2006
- Delineation of molecular changes in intrahepatic cholesterol metabolism resulting from diminished cholesterol absorptionJournal of Lipid Research, 2005
- Reduced expression of peroxisome proliferator‐activated receptor‐α may have an important role in the development of non‐alcoholic fatty liver diseaseJournal of Gastroenterology and Hepatology, 2004
- Acarbose attenuates experimental non-alcoholic steatohepatitisBiochemical and Biophysical Research Communications, 2004
- Niemann-Pick C1 Like 1 Protein Is Critical for Intestinal Cholesterol AbsorptionScience, 2004
- Isoform 1c of sterol regulatory element binding protein is less active than isoform 1a in livers of transgenic mice and in cultured cells.JCI Insight, 1997